Selenium and sulindac are synergistic to inhibit intestinal tumorigenesis in Apc/p21 mice by Xiuli Bi et al.
JOURNAL OF HEMATOLOGY
& ONCOLOGY
Bi et al. Journal of Hematology & Oncology 2013, 6:8
http://www.jhoonline.org/content/6/1/8SHORT REPORT Open AccessSelenium and sulindac are synergistic to inhibit
intestinal tumorigenesis in Apc/p21 mice
Xiuli Bi1,2, Nicole Pohl2, Huali Dong3 and Wancai Yang2,4*Abstract
Background: Both selenium and non-steroidal anti-inflammatory drug (NSAID) sulindac are effective in cancer
prevention, but their effects are affected by several factors including epigenetic alterations and gene expression.
The current study was designed to determine the effects of the combination of selenium and sulindac on tumor
inhibition and the underlying mechanisms.
Results: We fed the intestinal tumor model Apc/p21 mice with selenium- and sulindac-supplemented diet for 24
weeks, and found that the combination of selenium and sulindac significantly inhibited intestinal tumorigenesis, in
terms of reducing tumor incidence by 52% and tumor multiplicities by 80% (p<0.01). Mechanistic studies revealed
that the combination of selenium and sulindac led to the significant induction of the expression of p27 and p53
and JNK1 phosphorylation, and led to the suppression of β-catenin and its downstream targets. Impressively, the
data also showed that demythelation on p21 promoter was associated with tumor inhibition by the combination of
selenium and sulindac.
Conclusions: The selenium is synergistic with sulindac to exert maximal effects on tumor inhibition. This finding
provides an important chemopreventive strategy using combination of anti-cancer agents, which has a great
impact on cancer prevention and has a promising translational potential.
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Sulindac is a non-steroidal anti-inflammatory drug (NSAID)
that has shown to be effective in preventing intestinal
tumors in familial adenomatosis polyposis patients that in-
herit a mutant allele of the adenomatosis polyposis coli
(APC) gene [1,2], in inhibiting tumor formation in mouse
genetic models (ApcMin and Apc1638N+) in which an al-
lele of the homologous mouse Apc gene is inactivated by a
mutation [3-5], and in inhibiting carcinogen-induced colon
tumor formation in rats [6]. Our previously studies have
demonstrated that loss of p21WAF1/Cip1 gene could
enhance intestinal tumorigenesis in the Apc mouse
model (i.e. Apc/p21 mice) [7]. Most interestingly, diet-
ary supplemental sulindac was able to inhibit tumor
formation in the Apc+/−/p21+/+ mice, but not in the* Correspondence: wancaiyang@xxmu.edu.cn
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reproduction in any medium, provided the ormice in which even a single p21 allele was inactivated
(i.e. Apc+/−/p21+/−) [3], because the remaining wild-
type p21 allele is inactivated by hypermethylation of a
CpG cluster in its promoter in both the intestinal mucosa
as well as in the tumors that form [8]. To determine
whether the hypermethylated mouse p21 promoter could
be demethylated, and then the response to sulindac on in-
testinal tumor formation could be resumed, we fed the
Apc/p21 mice with diets supplemented with selenium or
combination of selenium and sulindac in present study to
determine the intestinal tumor inhibition.
Selenium, an important trace element, is essentially
involved in different physiological functions in mamma-
lian and human body. Selenium has significant activity as
a chemoprevention agent for cancer. Epidemiological and
experimental studies have suggested that intake of dietary
selenium is inversely related to overall cancer risk. The ef-
fect was most pronounced in gastrointestinal and prostate
cancer [9-11]. In addition, in vivo studies have demon-
strated that dietary selenium supplementation can reduce
cancer incidence in animal models of melanoma andhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Combination of selenium and sulindac significantly
inhibited intestinal tumor incidence (A) and multiplicities (B) in
the Apc/p21+/− mice. The mice were fed AIN-76A, AIN-76A plus
selenium or AIN-76A plus selenium and sulindac diet for 24 weeks
(p<0.01, compared to the mice fed AIN-76A diet). “Se” stands for
AIN-76A+selenium; “Se+Sul” stands for AIN-76A+selenium +sulindac.
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kidney and lung [10,11]. The anti-cancer effects of sele-
nium have been postulated to link to inhibition of cell
proliferation and induction of apoptosis through different
signaling pathways, particularly the anti-oxidative and
anti-inflammatory effects mediated through the activity of
selenoenzymes [12]. While the targets and underlying
mechanisms of anti-cancer action by selenium are largely
unknown. Recently, our group found that sodium selenite
inhibits intestinal carcinogenesis in vivo and in vitro
through a novel anti-cancer mechanism - activating JNK1
and suppressing β-catenin signaling [13], in addition to
the action of selenium of impacting methylation by inhi-
biting DNA methyltransferase [14,15].
The unique Apc/p21 mouse model of intestinal tumor
was applied in the current student. We found that sele-
nium was synergistic with sulindac and exerted max-
imum tumor inhibition efficacy through inhibiting p21
promoter methylation, inducing p53, p27 and phosphor-
ylation of JNK1, and suppressing Wnt/β-catenin signal-
ing, although selenium alone showed slight inhibitory
effect in the Apc/p21 mice.
Results
Combination of selenium and sulindac significantly
decreased intestinal tumorigenesis in Apc+/−/p21+/− mice
In consistent with our earlier report [7], loss of p21
increased Apc-initiated intestinal tumorigenesis. Ap-
proximately 95% (18/19) of the Apc+/−/p21+/− mice
spontaneously developed intestinal tumors when they
fed with the AIN-76A defined diet, at average multiplicities
of 1.95 per mouse (Figure 1). Selenium alone slightly inhib-
ited intestinal tumor formation in the Apc+/−/p21+/−
mice, tumor incidence decreased to 88% (23/26) and
tumor multiplicity decreased to 1.66, the differences were
not significant (P> 0.05), in comparison with the mice fed
the AIN-76A diet.
Our earlier study also reported that sulindac did
not exert tumor inhibition in Apc+/−/p21+/− and
Apc+/−/p21−/− mice although sulindac inhibited tumori-
genesis in the Apc+/−/p21+/+ mice in which both P21
alleles were wild-type [3]. However, the combination of
sulindac and selenium showed significant tumor inhibition
in the Apc/p21 mice in the present study. As shown in
Figure 1, when the mice were fed the diet supplemen-
ted with both sodium selenite and sulindac, intestinal
tumor incidence decreased 52% from 95% to 43% (6/14)
(Figure 1A) and tumor multiplicities decreased about 80%
from 1.95 to 0.4 per mouse (Figure 1B). Compared to the
AIN-76A group, the differences of tumor incidence and
multiplicity were significant, (p<0.01). These data strongly
suggested that selenium be synergistic to sulindac and
exert better chemopreventive effects on intestinal tumor
formation in the Apc+/−/p21+/− mice.Intestinal tumor inhibition by selenium and sulindac was
associated with suppressing Wnt/β-catenin signaling
pathway
To elucidate underlying mechanisms of tumor inhibition
by selenium and sulindac, the potential changes of mole-
cules involved in Wnt-β-catenin signaling pathways were
determined. As shown in Figure 2, in comparison with
the AIN-76A group, combination of selenium and sulin-
dac significantly suppressed the expression of β-catenin,
cyclin D1 and cdk4 by 2.6-fold, 100-, and 4.2-fold, re-
spectively. Interestingly, inflammatory marker Cox2 was
also decreased by 2.7-fold. In contrast, phosphorylated
JNK1 (active form of JNK1) was increased 2.7-fold, p27
was increased 2-fold and p53 was upregulated by 57-fold
in the mouse intestinal epithelial cells treated with the
combination of selenium and sulindac. However, com-
pared to the AIN-76A control group, the protein levels











Figure 2 A. Protein alterations by selenium and sulindac in intestinal epithelial cells from the Apc+/−/p21+/− mice, assayed by
immunoblotting. B. Quantification of protein intensity by Quanty One. “Se” stands for AIN-76A+selenium; “Se+Sul” stands for AIN-76A+selenium
+sulindac. (p<0.01, compared to the mice fed AIN-76A diet).
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which might explain its non-significant effect on tumor
inhibition. It is noted that since sulindac alone was not
sufficient to inhibit intestinal tumorigenesis in the Apc/
p21+/− mice [3], and the p21 protein was not inducible
in intestinal epithelial cells from the Apc/p21+/− [3,8],
no further molecular markers were determine in the
sulindac alone mouse group in current study.
Selenium and sulindac synergistically affected mouse p21
promoter methylation
Our previous study has demonstrated that the distal
CpG region of mouse promoter of the remaining wild-
type p21 allele was hypermethylated in intestinal epithe-
lial cells [8]. To gain further insight into the mechanisms
by which selenium could be synergistic with the sulindac
to exert tumor inhibition in the Apc+/−/p21+/− mice,
the impact on p21 promoter methylation status was
evaluated using the isolated intestinal epithelial cells
from different mouse groups, and the methylation-
specific PCR was performed. Consistent with our pre-
vious report, mouse p21promoter distal CpG region washypermethylated in intestinal epithelial cells of the
Apc+/−/p21+/− mice. Selenium and sulindac synergistic-
ally impacted mouse p21 promoter methylation, although
selenium alone did not (Figure 3). As one allele of p21 in
the Apc/p21+/− mice was lost, p21 protein levels were
very low and were not induced by sulindac [8] or selenium
alone, the induction of p21 protein by the combination of
selenium and sulindac was not obvious, and the induction
of p21 mRNA was not significant either (data not shown),
assayed by immunoblotting and quantitative RT-PCR as
described previously [8].
Discussion
Epigenetic alterations, particularly hypermethylation of
CpG islands located in the promoter regions of tumor sup-
pressor genes, contribute to tumor formation. Therefore,
developing chemopreventive strategies using the agents
targeting methylation will have great translational poten-
tial. Using the unique mouse model of intestinal tumors in
this study, incorporating with our earlier results [3,4,8], we
found that trace element selenium and sulindac synergis-
tically inhibited intestinal tumor formation.
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Figure 3 Combination of selenium and sulindac impacted p21 promoter methylation in intestinal epithelial cells of Apc/p21+/− mice
(A). “Se” stands for AIN-76A+selenium; “Se+Sul” stands for AIN-76A+selenium +sulindac. B. Quantification of the MS-PCR band intensity in
individual mouse. C, Overall average of the MS-PCR band intensity in each group. In AIN-76A and Se alone group, the methylation was higher
than unmethylation (*p<0.05, compared to the unmethylation groups), but in Se + Sul groups, the methylation status was significantly reversed
into unmethylation (**p<0.01, compared to the unmethylation groups).
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effective in preventing tumorigenesis. For instance, se-
veral randomized controlled trials have demonstrated
significant cancer prevention of selenium in colorectal
cancer [16-19] and in Muc2/p21 mouse model of intes-
tinal cancer reported recently by us [13]. However, the
selenium and vitamin E clinical trial (SELECT) on pros-
tate cancer prevention was failed and had to be termi-
nated earlier [20], although several factors should be
considered. In the current Apc/p21 mouse model, selen-
ium alone showed slight effect on tumor inhibition. It
has been demonstrated that anti-cancer action of sele-
nium is through multiple mechanisms. One of the novel
mechanisms is to impact methylation. Unlike previous
reports, we observed slight tumor inhibitory effect of
selenium, and almost no effect on methylation. Sulindac
alone has not been reported any demethylation or in-
hibitory effect on DNA transmethylferase. However, the
combination of selenium and sulindac dramatically
inhibited tumor formation and significantly affected
mouse p21 promoter methylation level. Therefore, this
combination of selenium and sulindac could pave a new
path for cancer prevention, and had promising transla-
tional significance.Our mechanistic study provided further insight of the
combination of selenium and sulindac in cancer preven-
tion, for example, selenium was synergistic with sulindac
to suppress Wnt/β-catenin signaling and induce Wnt/β-
catenin inhibitors. It is worth to point out that, the com-
bination of selenium and sulindac significantly induced
the expression of p27 and p53 and phosphorylation of
JNK1. It is well known that abnormally low levels of p27
protein are frequently found in human carcinomas, and
these low levels are directly correlated with histological
aggressiveness, lymph node metastasis and poor progno-
sis of esophagus, gastric, breast and colorectal carci-
nomas [21,22]. Overexpression of p27 and p53 could
downregulate β-catenin and its downstream targets, in-
hibit cell proliferation and promote cell differentiation
and apoptosis [23-25]. Most importantly, phosphorylated
JNK1 plays a critical role in intestinal cell maturation,
e.g. inducing apoptosis and differentiation and inhibiting
proliferation [26] through negatively interacting with
β-catenin and facilitating β-catenin degradation in vivo
and in vitro [27,28]. There are a lot of JNK1 stimulat-
ing agents, among them, both selenium and sulindac
are most effective in activating JNK1 [13,29]. Thus, the
combination of selenium and sulindac could exhibit
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These results were different with our previous study in
another mouse model of intestinal cancer – Muc2/p21
mice [13], in which we found that selenium supple-
mented in the Western-style high risk diet was able to
inhibit intestinal tumorigenesis and the selenium alone
was likely to induce JNK1 phosphorylation and to in-
hibit β-catenin and Cox-2. The causes of this discre-
pancy could be resulted from the differences of mouse
model backgrounds and diets. In that study [13], the
Muc2/p21 model was generated from mating p21−/−
mice with Muc2 knockout mice, in which Muc2 gene
plays a critical role in causing tumor formation and β-
catenin is inactivated [30]; in the current study, the
Apc/p21 mice were generated from mating of p21−/−
mice with Apc1638+/− mice, in which Apc mutation
plays a causing role on tumor formation because
β-catenin is activated [31]. In addition, in the previous
study, sodium selenite was added into the high-risk
Western-style diet with high-fat and low-vitamin D; in
the current study, the selenium was added into a
defined AIN-76A control diet.
With novel signaling pathways involving in carcino-
genesis and angiogenesis have been discovered, whether
preventive or therapeutic agents can target to these
pathways are large unknown. For example, the polo-like
kinase 3 (Plk3) has been recently found to phosphorylate
and destabilize hypoxia-inducible factor 1α (HIF-1α).
Plk3 can also phosphorylate and stabilize PTEN phos-
phatase, a known regulator of HIF-1α and tumor angio-
genesis [32]. Whether the combination of selenium and
sulindac can target on Plk3-HIF-1α-PTEN signaling, for
colorectal cancer prevention and therapy, is under investi-
gation. Recent reports have shown that gastrointestinal
stromal tumors (GIST) account for approximately 1% to
3% of all malignant GI tumors [33], but the treatment for
GIST is still a big challenge. Whether the combination of
selenium and sulindac has similar effects on GIST preven-
tion is unknown and needs to be investigated.
In conclusion, selenium and sulindac are synergistic to
inhibit intestinal tumorigenesis in the Apc/p21+/− mice
through impacting methylation, inducing the expression
of p27, p53 and phosphorylation of JNK1, and suppres-
sing β-catenin signaling. Current finding provides an im-
portant chemopreventive strategy using combination of
anti-cancer agents instead of a single one. Therefore, the
finding from this study has a great impact on cancer
prevention and has a promising translational potential.
Materials and methods
Experimental animals and dietary supplementation:
As described previously [3,7,31], the Apc1638+/− mice were
mated with p21−/− mice to produce Apc1638+/−/p21+/−
mice. At weaning (approximately 3–4 weeks), littermateswere randomized to genetic/dietary groups and fed ad libi-
tum AIN-76A diet,AIN-76A diet supplemented with
0.00004% (4.0 ppm) sodium selenite or the AIN-76A diet
supplemented with 0.00004% (4.0 ppm) sodium selenite
and 0.02% (200 ppm) sulindac (Research Diets Inc., New
Jersey). The mice were weighed weekly and maintained on
diet for 24 weeks or until they exhibited significant weight
loss or other signs of extensive tumor formation. The ani-
mals were sacrificed by CO2 overdose, followed by cer-
vical dislocation, and rapidly dissected for evaluation of
tumors and fixation of tissues, as described previously
[4,26,34]. This study was carried out in strict accordance
with the recommendations in the Guide for the Care and
Use of Laboratory Animals of the National Institutes of
Health. The protocols were approved by the Animal Care
Committee of the University of Illinois at Chicago (Proto-
col Numbers: 06–196 and 09–088).
Mouse intestinal tumorigenesis analysis
The gastrointestinal tract from stomach through rectum
was removed. The entire intestinal tract was opened lon-
gitudinally, and the stomach opened along the greater
curvature to expose the mucosa. The full length of the
intestinal tract was immediately examined for neoplastic
lesions under a dissecting microscope. The location and
the macroscopic features of all mucosal growth were
recorded. Tumor incidence (percentage of mice with
tumor), multiplicity (number of tumors per mouse), and
size (tumor volume) were analyzed.
Mouse intestinal epithelial cells collection and
immunoblotting
Intestinal epithelial cells from each strain were isolated by
incubating opened mouse intestine from duodenum as
described recently [26,35]. Protein was extracted from the
cell pellets isolated from the intestinal epithelial cells.
Equal amounts of protein (30 μg) were size-fractionated
on a 10% SDS gel and transferred onto a nitrocellulose
membrane (Bio-Rad Laboratories, Hercules, CA) using a
semi-dry transfer system (Bio-Rad). After blocking in 5%
non-fat milk, blots were incubated with primary anti-
bodies against p-JNK, p53, p27, Cyclin D1, CDK4 and β-
catenin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA),
or β-actin (Sigma, St Louis, MO) for overnight at 4°C.
Blots were washed with PBS containing 0.1% Tween, and
incubated with secondary antibodies conjugated to HRP
for 2 hours at room temperature. Immunoreactive pro-
teins were visualized and analyzed. Immunoblotting in-
tensities were quantified using Quanty One software
(Bio-Rad, Hercules, CA).
Methylation-specific polymerase chain reaction (MS-PCR)
Genomic DNA was isolated using a Dneasy Tissue Kit
(Qiagen, Valencia, CA, USA) from the intestinal epithelial
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DNA methylation kit (Zymo Research, Irvine, CA)
according manufactory instruction. Briefly, under these
conditions, unmethylated cytosine was converted to uracil,
but 5’-methylcytosine remained as cytosine. The primers
for methylation-specific PCR were designed using Meth-
Primer as reported previously [8]. The primers for the dis-
tal CpG cluster (100 bp, from −775 to −676) were:
forward (−824 to −800) 50-TGGTTTGAGAATTGGATT
TAATTTT-30, reverse (−641 to −665) 50-TCCCAAAAA
ATCCCACTATATCTAA-30, as this region was reported
to play a critical role in the response to sulindac in our
previous study [8]. The thermal cycler was programmed
as following: denaturation at 95°C for 5 min, followed by
35 cycles of denaturation at 95°C for 45 s, annealing at
56°C for 45 s and extension at 72°C for 45 s, and then
72°C for 10 min at completion.
Statistical analyses
Values for the average of intestinal tumor numbers were
expressed as means ± SD. Analysis of variance was used
to compare data derived from Apc/p21 mice fed with
AIN-76A control diet, AIN-76A plus sodium selenite, or
AIN-76A plus sodium selenite and sulindac, to deter-
mine whether there was a significant effect of selenium
alone or synergistic effect of selenium and sulindac on
tumor prevention.
Findings
Combination of selenium and sulindac significantly
inhibited intestinal tumorigenesis, which was linked to
induction of the expression of p27 and p53 and JNK1
phosphorylation, suppression of β-catenin signaling and
demythelation on p21 promoter.
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